Under construction – not a live service
Sign in
Taking people in TaiwanNo phase

Studies blood samples to look for lung cancer signs

Observes whether blood-based markers can help assess lung cancer in adults.

Key facts

Who runs it
Pharus Taiwan, Inc.
Where
Hsinchu, TaiwanSee the site
Trial code
Registry title
An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers.
Status
Recruiting
People taking part
1,340 people, planned
Started
5 May 2024
Expected to end
31 Dec 2026
Type of study
Observational
Treatments tested
  • Collect blood sample
Record updated
19 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with lung nodules or masses seen on a low-dose CT scan who are due to have a medical procedure, and for adults with no significant CT findings as a control group.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Test group: lung nodules or masses seen on a low-dose CT (LDCT) or CT scan, with a medical operation scheduled. Control group: no significant CT findings, with either no nodules or nodules smaller than 6mm, on a scan done within 2 months before joining.
Earlier treatment
People in the test group must not have had treatment before. Control group people must not have had a blood transfusion (except their own blood) in the 2 months before joining.

Main reasons for not taking part

  • Any past diagnosis of cancer
  • Blood transfusion (except their own blood) within the 2 months before joining
  • Gene therapy within 1 year before joining
  • Any vaccination within 3 months before the blood sample is taken
  • Currently pregnant

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Female or male participants at least 18 years of age
  • Participants in the test group must have identified lung nodules or masses through low-dose computed tomography (LDCT)CT scan, and have a scheduled medical operation, which is not limited to surgical excision. Control group participants should have no significant findings in LDCT/CT scan displaying either no nodules, or nodules smaller than 6mm were assessed by investigators without clinically significant justification, through an axial resolution of 3 mm or less, within 2 months prior to their enrollment in the study
  • Participants in the test group should be treatment naïve
  • Ability to complete a questionnaire, comprehend and comply with the requirements of the study
  • Written informed consent, and authorization to use and disclose health information

Who cannot take part

  • Has received a blood transfusion (except for autologous blood transfusion) within the first two months prior to participating the trial
  • Has taken gene therapy within one year prior to participating the trial
  • Has any vaccinations within 3 months prior to blood sample collection
  • Has any history of cancer diagnosis
  • Has any severe acute or uncontrolled chronic lung disease such as pneumonia, lung abscess, acute exacerbation of COPD or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of Study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this Study
  • Is participating in a clinical trial (the non-intervention trial will be accepted)
  • Is currently pregnant

Where in Taiwan

  • Pharus Taiwan, Inc.Hsinchu, TaiwanContact: Director of Data ScienceTaking people

About the trial

What the trial wants to find out

The purpose of this study is to observe whether miRNA and DNA methylation collected through liquid biopsy can serve as a biomarker for evaluating lung cancer.

The group in the trial

  • control/test

    Participants in the test group must have identified lung nodules or masses through low-dose computed tomography (LDCT)CT scan, and have a scheduled medical operation, which is not limited to surgical excision. Control group participants should have no significant findings in LDCT/CT scan displaying either no nodules, or nodules smaller than 6mm were assessed by investigators without clinically significant justification.

    Treatment: Collect blood sample

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers
Plain-language title
Studies blood samples to look for lung cancer signsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 September 2025